Reynolds G P
Department of Biomedical Science, University of Sheffield, England.
Drugs. 1996 Jan;51(1):7-11. doi: 10.2165/00003495-199651010-00002.
The dopamine D4 receptor, recently identified by molecular biological techniques, is expressed in areas of the brain implicated in the pathophysiology of schizophrenia. Although it has a lower affinity than the D2 receptor for most antipsychotic drugs, the D4 receptor has a higher affinity for clozapine, which may explain the unique efficacy of clozapine in the treatment of schizophrenia. However, there is no association between genetic alterations of the D4 gene and either the development of schizophrenia or response to clozapine administration, nor is the absence of the receptor related to major neuropsychiatric deficits. The report of an increase in D4 receptor density in the striatum in schizophrenia has not been consistently confirmed. Thus, it appears that there is little to support the development of D4 antagonists as potential antipsychotic agents.
多巴胺D4受体是最近通过分子生物学技术鉴定出来的,它在大脑中与精神分裂症病理生理学相关的区域表达。尽管对于大多数抗精神病药物而言,它与D2受体相比亲和力较低,但D4受体对氯氮平具有更高的亲和力,这可能解释了氯氮平治疗精神分裂症的独特疗效。然而,D4基因的遗传改变与精神分裂症的发生或对氯氮平给药的反应之间并无关联,而且该受体的缺失也与主要的神经精神缺陷无关。关于精神分裂症患者纹状体中D4受体密度增加的报告尚未得到一致证实。因此,似乎几乎没有证据支持开发D4拮抗剂作为潜在的抗精神病药物。